Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] LIG D&A (079550) – DS Investment & Securities | Order Expansion · Iraq Cheongung-II Mass Production · Long-term Earnings Growth / 2026-08-07 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] LIG D&A (079550) – SK Securities | CapEx Expansion · Global Interceptor Shortage · Earnings Quality / 2026-08-10 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Supply Constraints · Earnings Surge / 2026-05-11 Research
  • [Research] Alteogen (196170) – Hana Securities | Core Business on Track · Favorable Deal Outlook · Keytruda Royalty Impact Reflected / 2026-02-19 Research
  • [IR] SK hynix (000660 / SKHY) – Q2 2025 Earnings Presentation / 2025-07-24 IR Room
  • About Korea Equity Lens & Privacy Policy About

[Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | Silicon Capacitor · ASP Expansion · Valuation Re-rating / 2026-05-26

Posted on May 26, 2026August 24, 2026 By ksb220805@gmail.com

Brokerage : Shinhan Securities

Analyst : Kangho Oh (R.A Jibeom Seo)

Investment Rating : BUY (Maintained)

Target Price : KRW 2,000,000 (Raised)

Core Momentum : Structural multi-year earnings expansion and valuation re-rating driven by a KRW 1.6 Trillion silicon capacitor contract win, robust ASP growth, and shifting valuation base to 2028(E)

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY (Maintained) / Target Price KRW 2,000,000 (Raised by +100% from KRW 1,000,000) (Closing price KRW 1,340,000 as of May 22, 2026; upside potential 49.3%)
  • Valuation Methodology: Shifted valuation benchmark base to 2028, applying Target P/E multiple of 49.6x (raised by +20%, applying 2024–2025 historical High peer average across Murata, Ibiden, and Unimicron) to 2028(E) EPS of KRW 40,378
  • Earnings Forecast Revisions (Previous vs. Revised):
    • 2026(E): Revenue KRW 13.5975 Trillion (+0.5%), Operating Profit KRW 1.6035 Trillion (+2.2%), Net Profit KRW 1.3677 Trillion (+2.1%)
    • 2027(E): Revenue KRW 16.8008 Trillion (+6.7%), Operating Profit KRW 2.9016 Trillion (+23.9%), Net Profit KRW 2.3421 Trillion (+23.4%)
    • 2028(E): Revenue KRW 20.6603 Trillion (+12.7%), Operating Profit KRW 3.9118 Trillion (+30.5%), Net Profit KRW 3.1441 Trillion (+32.6%)
  • Key Financial Metrics & Forecast:
    • Revenue (KRW): 2024 KRW 10.2941 Trillion → 2025 KRW 11.3145 Trillion → 2026(E) KRW 13.5975 Trillion → 2027(E) KRW 16.8008 Trillion → 2028(E) KRW 20.6603 Trillion
    • Operating Profit (KRW): 2024 KRW 735.0 Billion → 2025 KRW 913.3 Billion → 2026(E) KRW 1.6035 Trillion → 2027(E) KRW 2.9016 Trillion → 2028(E) KRW 3.9118 Trillion
    • Net Profit (Controlling) (KRW): 2024 KRW 679.1 Billion → 2025 KRW 706.1 Billion → 2026(E) KRW 1.3677 Trillion → 2027(E) KRW 2.3421 Trillion → 2028(E) KRW 3.1441 Trillion
    • Valuation Multiples (PER / PBR / ROE):
      • 2024: PER 14.3x, PBR 1.1x, ROE 8.2%
      • 2025: PER 28.3x, PBR 2.1x, ROE 7.7%
      • 2026(E): PER 76.5x, PBR 9.7x, ROE 13.5%
      • 2027(E): PER 44.6x, PBR 8.1x, ROE 19.9%
      • 2028(E): PER 33.2x, PBR 6.7x, ROE 22.2%

🚀 2. [Market Opportunities & Business Outlook]

  • Segmental Annual Performance Breakdown:
    • Component Division:
      • Revenue: 2025 KRW 5.1985 Trillion → 2026(E) KRW 6.5201 Trillion → 2027(E) KRW 8.8876 Trillion.
      • Operating Profit: 2025 KRW 609.3 Billion (11.7% OPM) → 2026(E) KRW 1.0138 Trillion (15.5% OPM) → 2027(E) KRW 2.0806 Trillion (23.4% OPM).
      • High capacity utilization above 90% driving operational leverage and product mix improvements.
    • Substrate Division:
      • Revenue: 2025 KRW 2.3018 Trillion → 2026(E) KRW 3.2656 Trillion → 2027(E) KRW 4.1343 Trillion.
      • Operating Profit: 2025 KRW 135.2 Billion (5.9% OPM) → 2026(E) KRW 441.8 Billion (13.5% OPM) → 2027(E) KRW 689.0 Billion (16.7% OPM).
    • Module Division:
      • Revenue: 2025 KRW 3.8141 Trillion → 2026(E) KRW 3.8117 Trillion → 2027(E) KRW 3.7789 Trillion.
      • Operating Profit: 2025 KRW 168.7 Billion (4.4% OPM) → 2026(E) KRW 147.9 Billion (3.9% OPM) → 2027(E) KRW 132.0 Billion (3.5% OPM).
  • Strategic Significance of Silicon Capacitor Contract (KRW 1.6 Trillion):
    • Disclosed a KRW 1.6 Trillion silicon capacitor supply agreement on May 20.
    • Crucial for AI GPU and ASIC power integrity, handling transient current spikes and efficiency requirements close to the chip die.
    • Represents net-new high-value AI demand rather than commodity MLCC cannibalization; manufactured on separate lines, lifting 2027 Component revenue forecasts by +11%.

📝 Editor’s Comment (Perspective)

The analyst views Samsung Electro-Mechanics not as a cyclical volume (Q) follower, but as an indispensable high-value hardware platform capturing pricing power (P) and structural growth in an AI demand-exceeds-supply environment. This perspective emphasizes the validation of long-term demand via the KRW 1.6 Trillion silicon capacitor LTA, operating leverage from Component fab utilization above 90% (driving 2027 Component OPM to 23.4%), and justified valuation expansion utilizing 2028 forward metrics (Target P/E 49.6x applied to 2028(E) EPS of KRW 40,378).

To evaluate whether this investment thesis unfolds as anticipated, key verification checkpoints include the ramp-up and separate revenue recognition of the KRW 1.6 Trillion silicon capacitor supply, maintaining Component capacity utilization above 90% toward KRW 2.0+ Trillion in Component operating profit by 2027, and achieving mid-teens OPM in the Substrate division. Progress on these fronts can be tracked via upcoming quarterly earnings announcements, investor relations presentations, and official periodic regulatory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] Samsung Electro-Mechanics (009150) – Hana Securities | Silicon Capacitor LTA · 800VDC Infrastructure · 2027 Operating Profit 3T / 2026-05-21
Next Post: [Research] Samsung Electro-Mechanics (009150) – SK Securities | Global Tier-1 Multiples · Passive-Substrate Synergy · Embedded & Si-Cap / 2026-05-26

Related Posts

  • [Research] LigaChem Biosciences (141080) – Eugene Investment & Securities | Pipeline Clinical Progression · Licensing Revenue · Earnings Turnaround / 2025-02-17 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | ADR Listing · HBM Pricing · Valuation Re-rating / 2026-06-30 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Order Visibility · Production Expansion · Middle East Deliveries / 2026-08-07 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Growth Engines · 2Q26 OPM Ramp-up · Substrate CapEx Doubling / 2026-05-04 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | LTA · Capex Discipline · Cycle Stability / 2026-01-28 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Biosimilar Growth · Facility Expansion · CMO Capacity Readiness / 2026-05-07 Research
  • [Research] LIG D&A (079550) – Shinhan Securities | 4Q25 One-off Shock · KRW 26.2T Backlog · Long-term Structural Growth / 2026-02-20 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Readout · ABL111 Phase 3 · Grabody B Expansion / 2026-04-07 Research
  • [Research] Celltrion (068270) – Daishin Securities | Merger Noise Resolution · Portfolio Expansion Leverage · CMO Revenue Visibility / 2026-05-19 Research
  • [Research] Samsung SDI (006400) – Kyobo Securities | AI Data Center BBU · Direct CSP Channels · 1Q Earnings Beat / 2026-04-29 Research
  • [IR] Samsung Electronics (005930) – Q1 2025 Earnings Presentation / 2025-04-30 IR Room
  • [IR] SK hynix (000660 / SKHY) – Q4 2024 Earnings Presentation / 2025-01-23 IR Room
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme